Edition:
India

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

52.21USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$52.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
339,405
52-wk High
$168.91
52-wk Low
$50.68

Chart for

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $6,492.51
Shares Outstanding(Mil.): 54.18
Dividend: --
Yield (%): --

Financials

BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR

* TESARO INC - EXPECT TO COMPLETE ENROLLMENT IN MSI-H ENDOMETRIAL COHORT OF GARNET TRIAL BY END OF YEAR Source text for Eikon: Further company coverage:

16 Apr 2018

BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel

* TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULA® IN ISRAEL

11 Apr 2018

BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer

* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER

27 Mar 2018

BRIEF-Tesaro Inc Q4 Loss Per Share $3.35

* TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS

28 Feb 2018

BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER

27 Feb 2018

BRIEF-Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion

* TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION

13 Jan 2018

Exclusive: U.S. cancer drugmaker Ignyta in advanced sale talks - sources

Ignyta Inc is in advanced talks to sell itself, people familiar with the matter said on Thursday, just three years after the U.S. cancer drugmaker became a public company focused on precision drugs and diagnostics.

22 Dec 2017

Exclusive: U.S. cancer drugmaker Ignyta in advanced sale talks - sources

Ignyta Inc is in advanced talks to sell itself, people familiar with the matter said on Thursday, just three years after the U.S. cancer drugmaker became a public company focussed on precision drugs and diagnostics.

22 Dec 2017

BRIEF-Tesaro secures $500 million non-dilutive term loan financing

* Tesaro secures $500 million non-dilutive term loan financing

21 Nov 2017

BRIEF-Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

* Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

20 Nov 2017

Earnings vs. Estimates